(1888 PressRelease) First successful spinal cord treatment using a non-invasive stem-cell topical drug.
New York, NY – The world’s first success in treating spinal cord injury sustained more than 40 years ago has been demonstrated using a new non-invasive drug.
The treatment relies on a new formulation that creates stem cells deep below the skin using a highly-penetrating ointment. The drug is delivered using technology similar to that used in nicotine patches. TetraStem is a new tetracycline-based topical antibiotic that is FDA registered to treat cuts and burns. It was discovered 5 years ago that, as a new off-label drug, it also can induce stem-cell healing; first in an animal research program followed by human research programs.
Older spinal cord injuries have been notoriously impossible to treat. Paraplegics and quadraplegics have tended to remain paraplegics and quadraplegics. Now, what was impossible may become possible using this new stem-cell drug. Good results have been obtained after treatment of a spinal cord injury sustained 42 years ago. The research methodology and case study results are online at http://www.PhillipsCompany.4T.com/SCAR.pdf
The new treatment is the world’s first low-cost treatment for spinal cord injury. Hospitalization is not required because the non-invasive stem-cell drug can be applied topically, and there are no known side effects. For a limited time, the manufacturer is offering the new drug to any paraplegic.
Miranda is the first patient to benefit from this simple but effective experimental drug. As a complete paraplegic, she became the first person on earth to walk again as result of using the simple rub-it-on-the-skin drug for six months. Miranda’s treatment and progress is reported online at http://www.PhillipsCompany.4T.com/Miranda.pdf
Because Miranda’s treatment began only a few days following her spinal cord injury, it was first thought that perhaps the successful outcome using the new drug might be helpful only as an early-intervention treatment — but a better expectation has been established based on recent data.
Phillips Company invites any hospital or orthopedic surgeon to evaluate this new drug for the treatment of patients with spinal cord injury.
The new ointment is being developed by the world’s only not-for-profit FDA-registered drug manufacturing company. Phillips Company is a develop-and-license company. TetraStem will be transferred to a larger pharmaceutical company for high-volume production.